# Rallybio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rallybio

- Industry: Biotechnology
- Headquarters: New Haven, US
- Website: www.rallybio.com
- Total disclosed funding: $182M
- Latest round: Series B (Mar 27, 2020)
- Investors on record: 12

## About

Founded in 2018 and based in Connecticut, US, Rallybio, LLC is a biotechnology company that develops therapeutics for the treatment of different severe and rare diseases. The firm was founded by Jeffrey Fryer, Martin Mackay, and Stephen Uden, and has raised a total funding of USD 275.2 million in 2020.
 
Rallybio, LLC develops therapeutics and uses small molecule and protein-based therapies that help health professionals in identifying the necessary therapy for a certain disease. Its primary aim is to avoid prenatal and neonatal alloimmune thrombocytopenia, a potentially fatal uncommon condition that can cause uncontrollable bleeding in fetuses and infants. The company develops programs for various therapeutic areas like maternal fetal blood disorders, complement dysregulation and metabolic disorders.

As of July 2021, Rallybio, LLC plans to become a public company under the ticker symbol RLYB on the Nasdaq.

## Funding rounds

- Series B, Mar 27, 2020, $145M — Fairview Capital Partners, TPG, Canaan Partners, Mitsui Global Investment, 5AM Ventures, New Leaf Venture Partners, Connecticut Innovations, Tekla Capital Management, F-Prime Capital, Viking Global Investors, Pivotal Life Sciences, Solasta Ventures
- Series A, Apr 25, 2018, $37M — Canaan Partners, 5AM Ventures, New Leaf Venture Partners, Connecticut Innovations

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series A, Series B
- Connecticut Innovations (https://capitalatlas.ai/funds/connecticut-innovations) — Series A, Series B
- Fairview Capital Partners (https://capitalatlas.ai/funds/fairview-capital-partners) — Series B
- TPG (https://capitalatlas.ai/funds/tpg) — Series B
- Mitsui Global Investment (https://capitalatlas.ai/funds/mitsui-global-investment) — Series B
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Series B
- Solasta Ventures (https://capitalatlas.ai/funds/solasta-ventures) — Series B